Abeona Therapeutics Inc Ret. on equity
What is the Ret. on equity of Abeona Therapeutics Inc?
The Ret. on equity of Abeona Therapeutics Inc is -207.85%
What is the definition of Ret. on equity?
Return on equity is a measure of the profitability of a business in relation to the book value of the shareholder equity. It is computed by dividing fiscal year net income by total shareholder equity.
ttm (trailing twelve months)
The return on equity (ROE) ROE is a measure of how well a company uses investments to generate earnings growth. ROE is used for comparing the performance of companies in the same industry. It indicated the management's ability to generate income from the equity available to it. ROEs of 15-20% are generally considered good. ROEs are also a factor in stock valuation, in association with other financial ratios. In general, stock prices are influenced by earnings per share (EPS), so that stock of a company with a 20% ROE will generally cost twice as much as one with a 10% ROE.
Ret. on equity of companies in the Health Care sector on NASDAQ compared to Abeona Therapeutics Inc
What does Abeona Therapeutics Inc do?
abeona therapeutics inc. (nasdaq: $abeo), is a leading clinical-stage biopharmaceutical company focused on developing novel gene therapies for life-threatening rare genetic diseases. abeona was forged from the company’s close collaborations with key stakeholders all dedicated to transforming new biotechnology insights into breakthrough treatments for rare diseases. abeona's lead programs include abo-102 (aav-sgsh), an adeno-associated virus (aav) based gene therapy for sanfilippo syndrome type a (mps iiia) and eb-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (rdeb). abeona is also developing abo-101 (aav-naglu) for sanfilippo syndrome type b (mps iiib), abo-201 (aav-cln3) gene therapy for juvenile batten disease (jncl), abo-202 (aav-cln1) for treatment of infantile batten disease (incl), eb-201 for epidermolysis bullosa (eb), abo-301 (aav-fancc) for fanconi anemia (fa) disorder and abo-302 using a novel crispr/cas9-based gene editing approach to gene t
Companies with ret. on equity similar to Abeona Therapeutics Inc
- BroadVision has Ret. on equity of -208.85%
- madvertise SA has Ret. on equity of -208.84%
- Nagreeka Capital & Infrastructure has Ret. on equity of -208.80%
- Nutritional Growth Solutions has Ret. on equity of -208.79%
- Predictmedix has Ret. on equity of -207.94%
- Avacta Plc has Ret. on equity of -207.87%
- Abeona Therapeutics Inc has Ret. on equity of -207.85%
- CG Power and Industrial Solutions has Ret. on equity of -207.51%
- Shiloh Industries has Ret. on equity of -207.37%
- RYU Apparel has Ret. on equity of -207.33%
- CruzSur has Ret. on equity of -207.06%
- Four Corners has Ret. on equity of -206.48%
- Score Media and Gaming has Ret. on equity of -206.47%